A citation-based method for searching scientific literature

William Hagopian, Robert J Ferry, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold, Johnny Ludvigsson. Diabetes 2013
Times Cited: 116







List of co-cited articles
1002 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
53

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
785
52

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
185
49

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
629
45

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
837
44

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
41

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
138
35

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
34

B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Mark D Pescovitz, Carla J Greenbaum, Brian Bundy, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Antoinette Moran, Philip Raskin,[...]. Diabetes Care 2014
115
29

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A Dimeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Diabetes Care 2014
110
29

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
68
42

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Michael J Haller, Stephen E Gitelman, Peter A Gottlieb, Aaron W Michels, Stephen M Rosenthal, Jonathan J Shuster, Baiming Zou, Todd M Brusko, Maigan A Hulme, Clive H Wasserfall,[...]. J Clin Invest 2015
93
29

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A Insel, Jessica L Dunne, Mark A Atkinson, Jane L Chiang, Dana Dabelea, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jeffrey P Krischer, Åke Lernmark,[...]. Diabetes Care 2015
327
25

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley,[...]. N Engl J Med 2019
190
25

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin,[...]. Lancet 2013
209
24

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Kevan C Herold, Stephen E Gitelman, Umesh Masharani, William Hagopian, Brygida Bisikirska, David Donaldson, Kristina Rother, Beverly Diamond, David M Harlan, Jeffrey A Bluestone. Diabetes 2005
459
24

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks,[...]. Lancet 2011
226
23

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
L Chatenoud, E Thervet, J Primo, J F Bach. Proc Natl Acad Sci U S A 1994
499
22

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
385
22


Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
Anette G Ziegler, Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck, Christiane Winkler, Jorma Ilonen, Riitta Veijola, Mikael Knip,[...]. JAMA 2013
523
21

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Carla J Greenbaum, Craig A Beam, David Boulware, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, John M Lachin, Paula McGee, Jerry P Palmer, Mark D Pescovitz,[...]. Diabetes 2012
191
20

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Stephen E Gitelman, Peter A Gottlieb, Mark R Rigby, Eric I Felner, Steven M Willi, Lynda K Fisher, Antoinette Moran, Michael Gottschalk, Wayne V Moore, Ashley Pinckney,[...]. Lancet Diabetes Endocrinol 2013
84
23

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
K C Herold, S E Gitelman, S M Willi, P A Gottlieb, F Waldron-Lynch, L Devine, J Sherr, S M Rosenthal, S Adi, M Y Jalaludin,[...]. Diabetologia 2013
69
27

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
S Alice Long, Mary Rieck, Srinath Sanda, Jennifer B Bollyky, Peter L Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2012
209
19

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Johnny Ludvigsson, David Krisky, Rosaura Casas, Tadej Battelino, Luis Castaño, James Greening, Olga Kordonouri, Timo Otonkoski, Paolo Pozzilli, Jean-Jacques Robert,[...]. N Engl J Med 2012
188
19

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Mark R Rigby, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Chetanbabu M Patel, Kurt J Griffin, Eva Tsalikian, Peter A Gottlieb,[...]. Lancet Diabetes Endocrinol 2013
106
19

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A Bluestone, Jane H Buckner, Mark Fitch, Stephen E Gitelman, Shipra Gupta, Marc K Hellerstein, Kevan C Herold, Angela Lares, Michael R Lee, Kelvin Li,[...]. Sci Transl Med 2015
480
18

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Kirsti Näntö-Salonen, Antti Kupila, Satu Simell, Heli Siljander, Tiina Salonsaari, Anne Hekkala, Sari Korhonen, Risto Erkkola, Jukka I Sipilä, Lotta Haavisto,[...]. Lancet 2008
241
17

GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson,[...]. N Engl J Med 2008
332
16

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
143
16

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
James E Tooley, Nalini Vudattu, Jinmyung Choi, Chris Cotsapas, Lesley Devine, Khadir Raddassi, Mario R Ehlers, James G McNamara, Kristina M Harris, Sai Kanaparthi,[...]. Eur J Immunol 2016
36
44

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
450
15

Genetics, pathogenesis and clinical interventions in type 1 diabetes.
Jeffrey A Bluestone, Kevan Herold, George Eisenbarth. Nature 2010
658
15


Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
15



Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
Jeffrey P Krischer, Desmond A Schatz, Brian Bundy, Jay S Skyler, Carla J Greenbaum. JAMA 2017
65
23

Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.
Hillary A Keenan, Jennifer K Sun, Jared Levine, Alessandro Doria, Lloyd P Aiello, George Eisenbarth, Susan Bonner-Weir, George L King. Diabetes 2010
316
14

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.
Ken T Coppieters, Francesco Dotta, Natalie Amirian, Peter D Campbell, Thomas W H Kay, Mark A Atkinson, Bart O Roep, Matthias G von Herrath. J Exp Med 2012
398
14

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Ezio Bonifacio, Anette-G Ziegler, Georgeanna Klingensmith, Edith Schober, Polly J Bingley, Marietta Rottenkolber, Anke Theil, Anne Eugster, Ramona Puff, Claudia Peplow,[...]. JAMA 2015
98
14

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Agnès Hartemann, Gilbert Bensimon, Christine A Payan, Sophie Jacqueminet, Olivier Bourron, Nathalie Nicolas, Michèle Fonfrede, Michelle Rosenzwajg, Claude Bernard, David Klatzmann. Lancet Diabetes Endocrinol 2013
232
13

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Júlio C Voltarelli, Carlos E B Couri, Ana B P L Stracieri, Maria C Oliveira, Daniela A Moraes, Fabiano Pieroni, Marina Coutinho, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2007
354
13

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
S Alice Long, Jerill Thorpe, Hannah A DeBerg, Vivian Gersuk, James Eddy, Kristina M Harris, Mario Ehlers, Kevan C Herold, Gerald T Nepom, Peter S Linsley. Sci Immunol 2016
74
17

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
Michael J Haller, Desmond A Schatz, Jay S Skyler, Jeffrey P Krischer, Brian N Bundy, Jessica L Miller, Mark A Atkinson, Dorothy J Becker, David Baidal, Linda A DiMeglio,[...]. Diabetes Care 2018
39
33

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.
Peter A Gottlieb, Scott Quinlan, Heidi Krause-Steinrauf, Carla J Greenbaum, Darrell M Wilson, Henry Rodriguez, Desmond A Schatz, Antoinette M Moran, John M Lachin, Jay S Skyler. Diabetes Care 2010
94
12


Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Bart Keymeulen, Sophie Candon, Samira Fafi-Kremer, Anette Ziegler, Marianne Leruez-Ville, Chantal Mathieu, Evy Vandemeulebroucke, Markus Walter, Laurent Crenier, Eric Thervet,[...]. Blood 2010
55
21

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Carlos E B Couri, Maria C B Oliveira, Ana B P L Stracieri, Daniela A Moraes, Fabiano Pieroni, George M N Barros, Maria Isabel A Madeira, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2009
266
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.